President Obama’s year-old, $200 million Precision Medicine initiative (PMI) seems to be doing exactly what was intended, writes Heather Gartman.
Heather Gartman
Advertisement
Heather Gartman is Regional Managing Director (DC), inVentiv Health
Articles by Heather Gartman
Advertisement
Latest Updated Articles
- What “Precision Medicine” Means for Rare Diseases
Published: March 3rd 2016 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Novartis Planning Layoffs for 550 Positions at Switzerland Facility
2
How Technology is Moving the Industry Away from Animal Testing: Q&A with Dr. Jo Varshney
3
How Do New GLP-1 Drugs Impact Businesses' Ability to Provide Them to Employees?
4
Next-Gen CDMOs: Keeping Pace With Industry Change
5
